Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever. 2016

Rosemary Wyber, and Ben J Boyd, and Samantha Colquhoun, and Bart J Currie, and Mark Engel, and Joseph Kado, and Ganesan Karthikeyan, and Mark Sullivan, and Anita Saxena, and Meru Sheel, and Andrew Steer, and Joseph Mucumbitsi, and Liesl Zühlke, and Jonathan Carapetis
Telethon Kids Institute, University of Western Australia, 100 Roberts Road, Subiaco, Western Australia, 6008, Australia. Rosemary.Wyber@telethonkids.org.au.

Rheumatic fever is caused by an abnormal immune reaction to group A streptococcal infection. Secondary prophylaxis with antibiotics is recommended for people after their initial episode of rheumatic fever to prevent recurrent group A streptococcal infections, recurrences of rheumatic fever and progression to rheumatic heart disease. This secondary prophylaxis must be maintained for at least a decade after the last episode of rheumatic fever. Benzathine penicillin G is the first line antibiotic for secondary prophylaxis, delivered intramuscularly every 2 to 4 weeks. However, adherence to recommended secondary prophylaxis regimens is a global challenge. This paper outlines a consultation with global experts in rheumatic heart disease on the characteristics of benzathine penicillin G formulations which could be changed to improve adherence with secondary prophylaxis. Characteristics included dose interval, pain, administration mechanism, cold chain independence and cost. A sample target product profile for reformulated benzathine penicillin G is presented.

UI MeSH Term Description Entries
D010401 Penicillin G Benzathine Semisynthetic antibiotic prepared by combining the sodium salt of penicillin G with N,N'-dibenzylethylenediamine. Benzathine Penicillin,Bencelin,Benzathine Benzylpenicillin,Benzathine Benzylpénicilline Panpharma,Benzetacil,Bicillin,Bicillin L-A,Brevicilina,Cepacilina,Debecillin,Extencilline,Pendepon,Penduran,Pendysin,Penicillin G Benzathine Anhydrous,Penidural,Peniroger Retard,Permapen,Provipen Benzatina,Tardocillin,Benzathine, Penicillin G,Benzylpenicillin, Benzathine,Bicillin L A,Bicillin LA,Penicillin, Benzathine
D004339 Drug Compounding The preparation, mixing, and assembly of a drug. (From Remington, The Science and Practice of Pharmacy, 19th ed, p1814). Drug Formulation,Drug Preparation,Drug Microencapsulation,Pharmaceutical Formulation,Compounding, Drug,Formulation, Drug,Formulation, Pharmaceutical,Microencapsulation, Drug,Preparation, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001291 Attitude of Health Personnel Attitudes of personnel toward their patients, other professionals, toward the medical care system, etc. Staff Attitude,Attitude, Staff,Attitudes, Staff,Health Personnel Attitude,Health Personnel Attitudes,Staff Attitudes
D012213 Rheumatic Fever A febrile disease occurring as a delayed sequela of infections with STREPTOCOCCUS PYOGENES. It is characterized by multiple focal inflammatory lesions of the connective tissue structures, such as the heart, blood vessels, and joints (POLYARTHRITIS) and brain, and by the presence of ASCHOFF BODIES in the myocardium and skin. Acute Rheumatic Fever,Arthritis, Rheumatic, Acute,Rheumatism, Articular, Acute,Arthritis, Acute Rheumatic,Inflammatory Rheumatism,Polyarthritis Rheumatica,Rheumatic Arthritis,Rheumatism, Acute Articular,Acute Articular Rheumatism,Acute Articular Rheumatisms,Acute Rheumatic Arthritides,Acute Rheumatic Arthritis,Acute Rheumatic Fevers,Arthritis, Rheumatic,Articular Rheumatism, Acute,Fever, Acute Rheumatic,Fever, Rheumatic,Fevers, Acute Rheumatic,Inflammatory Rheumatisms,Polyarthritis Rheumaticas,Rheumatic Arthritides,Rheumatic Arthritis, Acute,Rheumatic Fever, Acute,Rheumatic Fevers,Rheumatism, Inflammatory
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug
D055502 Secondary Prevention The prevention of recurrences or exacerbations of a disease or complications of its therapy. Disease Prevention, Secondary,Early Therapy,Relapse Prevention,Secondary Disease Prevention,Disease Preventions, Secondary,Early Therapies,Prevention, Relapse,Prevention, Secondary,Prevention, Secondary Disease,Preventions, Relapse,Preventions, Secondary,Preventions, Secondary Disease,Relapse Preventions,Secondary Disease Preventions,Secondary Preventions,Therapies, Early,Therapy, Early

Related Publications

Rosemary Wyber, and Ben J Boyd, and Samantha Colquhoun, and Bart J Currie, and Mark Engel, and Joseph Kado, and Ganesan Karthikeyan, and Mark Sullivan, and Anita Saxena, and Meru Sheel, and Andrew Steer, and Joseph Mucumbitsi, and Liesl Zühlke, and Jonathan Carapetis
March 1994, The Ceylon medical journal,
Rosemary Wyber, and Ben J Boyd, and Samantha Colquhoun, and Bart J Currie, and Mark Engel, and Joseph Kado, and Ganesan Karthikeyan, and Mark Sullivan, and Anita Saxena, and Meru Sheel, and Andrew Steer, and Joseph Mucumbitsi, and Liesl Zühlke, and Jonathan Carapetis
January 1959, Rocky Mountain medical journal,
Rosemary Wyber, and Ben J Boyd, and Samantha Colquhoun, and Bart J Currie, and Mark Engel, and Joseph Kado, and Ganesan Karthikeyan, and Mark Sullivan, and Anita Saxena, and Meru Sheel, and Andrew Steer, and Joseph Mucumbitsi, and Liesl Zühlke, and Jonathan Carapetis
October 1993, The Journal of pediatrics,
Rosemary Wyber, and Ben J Boyd, and Samantha Colquhoun, and Bart J Currie, and Mark Engel, and Joseph Kado, and Ganesan Karthikeyan, and Mark Sullivan, and Anita Saxena, and Meru Sheel, and Andrew Steer, and Joseph Mucumbitsi, and Liesl Zühlke, and Jonathan Carapetis
June 1996, Pediatrics,
Rosemary Wyber, and Ben J Boyd, and Samantha Colquhoun, and Bart J Currie, and Mark Engel, and Joseph Kado, and Ganesan Karthikeyan, and Mark Sullivan, and Anita Saxena, and Meru Sheel, and Andrew Steer, and Joseph Mucumbitsi, and Liesl Zühlke, and Jonathan Carapetis
April 1984, Pediatrics,
Rosemary Wyber, and Ben J Boyd, and Samantha Colquhoun, and Bart J Currie, and Mark Engel, and Joseph Kado, and Ganesan Karthikeyan, and Mark Sullivan, and Anita Saxena, and Meru Sheel, and Andrew Steer, and Joseph Mucumbitsi, and Liesl Zühlke, and Jonathan Carapetis
November 1996, Arquivos brasileiros de cardiologia,
Rosemary Wyber, and Ben J Boyd, and Samantha Colquhoun, and Bart J Currie, and Mark Engel, and Joseph Kado, and Ganesan Karthikeyan, and Mark Sullivan, and Anita Saxena, and Meru Sheel, and Andrew Steer, and Joseph Mucumbitsi, and Liesl Zühlke, and Jonathan Carapetis
January 1992, Indian journal of pediatrics,
Rosemary Wyber, and Ben J Boyd, and Samantha Colquhoun, and Bart J Currie, and Mark Engel, and Joseph Kado, and Ganesan Karthikeyan, and Mark Sullivan, and Anita Saxena, and Meru Sheel, and Andrew Steer, and Joseph Mucumbitsi, and Liesl Zühlke, and Jonathan Carapetis
May 1994, Antimicrobial agents and chemotherapy,
Rosemary Wyber, and Ben J Boyd, and Samantha Colquhoun, and Bart J Currie, and Mark Engel, and Joseph Kado, and Ganesan Karthikeyan, and Mark Sullivan, and Anita Saxena, and Meru Sheel, and Andrew Steer, and Joseph Mucumbitsi, and Liesl Zühlke, and Jonathan Carapetis
February 2001, Indian journal of pediatrics,
Rosemary Wyber, and Ben J Boyd, and Samantha Colquhoun, and Bart J Currie, and Mark Engel, and Joseph Kado, and Ganesan Karthikeyan, and Mark Sullivan, and Anita Saxena, and Meru Sheel, and Andrew Steer, and Joseph Mucumbitsi, and Liesl Zühlke, and Jonathan Carapetis
July 1993, The Journal of pediatrics,
Copied contents to your clipboard!